The toxicity pattern of d-penicillamine therapy
| Autor: | I. L. Dwosh, Walter F. Kean, P. M. Ford, H. Garfield Kelly, Tassos Anastassiades |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
medicine.medical_specialty
Proteinuria business.industry Immunology Penicillamine Arthritis medicine.disease Gastroenterology Surgery Drug withdrawal Dose–response relationship Rheumatology Rheumatoid arthritis Internal medicine Toxicity Immunology and Allergy Medicine Pharmacology (medical) medicine.symptom Risk factor business medicine.drug |
| Zdroj: | Arthritis & Rheumatism. 23:158-164 |
| ISSN: | 1529-0131 0004-3591 |
| Popis: | One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine. After a mean total followup of 11.5 months (38 patients have completed 2 years of followup) there was a 70% overall improvement rate with 2 complete remissions. Sixty-one patients developed 84 separate toxic reactions, 36 of which required drug withdrawal. Skin rashes (27/84), proteinuria (15/84), low platelets (14/84), and taste abnormalities (10/84) were the most common side effects of therapy at a mean D-penicillamine dose of 463 mg/day. The majority of toxic reactions (85%) occurred in the first 6 months, but proteinuria and thrombocytopenia were more common in the 6 to 12 month treatment period. Previous gold toxicity was a risk factor for developing D-penicillamine toxicity (10/13). Our observations suggest that D-penicillamine related toxicity is a major problem even at 500 mg/day, but the drug can be used with an increased safety margin after 9 months of continuous therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text